JP2023514347A5 - - Google Patents

Info

Publication number
JP2023514347A5
JP2023514347A5 JP2022549518A JP2022549518A JP2023514347A5 JP 2023514347 A5 JP2023514347 A5 JP 2023514347A5 JP 2022549518 A JP2022549518 A JP 2022549518A JP 2022549518 A JP2022549518 A JP 2022549518A JP 2023514347 A5 JP2023514347 A5 JP 2023514347A5
Authority
JP
Japan
Prior art keywords
patient
here
transplant
approximately
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/018599 external-priority patent/WO2021168128A1/en
Publication of JP2023514347A publication Critical patent/JP2023514347A/ja
Publication of JP2023514347A5 publication Critical patent/JP2023514347A5/ja
Pending legal-status Critical Current

Links

JP2022549518A 2020-02-18 2021-02-18 同種移植のための組成物及び方法 Pending JP2023514347A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062978141P 2020-02-18 2020-02-18
US62/978,141 2020-02-18
US202063062845P 2020-08-07 2020-08-07
US63/062,845 2020-08-07
PCT/US2021/018599 WO2021168128A1 (en) 2020-02-18 2021-02-18 Compositions and methods for allogeneic transplantation

Publications (2)

Publication Number Publication Date
JP2023514347A JP2023514347A (ja) 2023-04-05
JP2023514347A5 true JP2023514347A5 (cg-RX-API-DMAC7.html) 2024-02-26

Family

ID=77391794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549518A Pending JP2023514347A (ja) 2020-02-18 2021-02-18 同種移植のための組成物及び方法

Country Status (10)

Country Link
US (1) US20230390412A1 (cg-RX-API-DMAC7.html)
EP (1) EP4107188A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023514347A (cg-RX-API-DMAC7.html)
KR (1) KR20220154676A (cg-RX-API-DMAC7.html)
CN (1) CN115397444A (cg-RX-API-DMAC7.html)
AU (1) AU2021224663A1 (cg-RX-API-DMAC7.html)
CA (1) CA3168039A1 (cg-RX-API-DMAC7.html)
IL (1) IL295653A (cg-RX-API-DMAC7.html)
MX (1) MX2022009885A (cg-RX-API-DMAC7.html)
WO (1) WO2021168128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020376934A1 (en) * 2019-11-01 2022-06-02 Regeneron Pharmaceuticals, Inc. Anti-CD45 antibodies and conjugates thereof
US12496303B2 (en) * 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170226209A1 (en) * 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
HK1256681A1 (zh) * 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
CN118662615A (zh) * 2017-03-15 2024-09-20 浩康生物系统公司 用于造血干细胞移植的组合物和方法

Similar Documents

Publication Publication Date Title
JP6018622B2 (ja) Cd37結合性分子及びその免疫複合体
Sullivan-Chang et al. Targeting CD22 in B-cell malignancies: current status and clinical outlook
JP2022512781A5 (cg-RX-API-DMAC7.html)
US20230110128A1 (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
JP2022163075A (ja) 細胞の枯渇のための組成物および方法
ES2882360T3 (es) Inmunoempobrecimiento selectivo de un nicho de células madre endógenas para injerto
US20210379195A1 (en) Methods for allogeneic hematopoietic stem cell transplantation
Persaud et al. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation
JP2018522833A (ja) キメラ抗原受容体(car)コンストラクト、及びcarコンストラクトを発現するt細胞(car−t)またはnk細胞(car−nk)による疾患治療
HUE031533T2 (hu) CD19-kötõszerek valamint alkalmazásuk
US7498023B2 (en) Blockade of T cell migration into epithelial GVHD target tissues as an approach to achieving anti-tumor effects against lymphohematopoietic malignancies without GVHD
CN116940386A (zh) 吡咯并苯并二氮杂䓬-抗体缀合物以及其用途
Cipkar et al. Antibodies and bispecifics for multiple myeloma: effective effector therapy
CN102271711A (zh) 每种维持移植物抗肿瘤效应的免疫重建促进剂或感染预防剂
US20240245753A1 (en) Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
CA3114922A1 (en) Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
CA3183602A1 (en) Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
US20220273811A1 (en) Methods and compositions for treating autoimmune diseases
US20220347313A1 (en) Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers
ES2213355T3 (es) Cocteles de inmunotoxinas para el tratamiento de enfermedades de origen inmunologico.
EP4054647A1 (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
Routledge Belantamab mafodotin. Antibody-drug conjugate targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma
CN120359242A (zh) 靶向cd117和cd3的双特异性抗体
yuan Teo et al. Monoclonal Antibodies in Lymphoma
HK40077034A (en) Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers